FibroTest is a patented biomarker test that uses the results of six blood serum tests to generate a score that is correlated with the degree of liver damage in people with a variety of liver diseases. FibroTest has the same prognostic value as a liver biopsy.

The numbers of people at risk of liver fibrosis, cirrhosis and hepatocellular carcinoma are alarming, and even more alarming is the number of patients suffering from liver diseases around the globe that go undiagnosed.

Traditional liver biopsy used to estimate the degree of liver damage is undesirable to patients and associated with serious complications and drawbacks such as:

  • It is invasive
  • It is prone to complications
  • It is painful to many patients
  • There is a considerable sampling variability
  • There is a high intra and inter-pathologist variability
Today's advances and innovations in medical technology have created a Fibro diagnostic test that provides accurate and instant results.

Biochemical Markers provide highly accurate results for the diagnosis of the most common liver diseases using an algorithm based on the patients sex, age, weight, height and specific blood biomarkers (alpha-2 macroglobulin, haptoglobin, apolipoprotein A1, Total bilirubin, GGT, and ALT).

These algorithms have been scientifically validated and quality-monitored to ensure that the results delivered are the highest analytical standards. The validation and analytical standardization have been established in many clinical studies. There are over 40 publications that review and assess these tests; these can be found at www.biopredictive.com

Who is a Candidate for Fibro Test?

  • Insulin resistant Patients
  • Alcoholic Patients (ALD)
  • Hepatitis B Patients
  • Hepatitis C Patients
  • Non- alcoholic fatty liver disease (NAFLD)

Test Procedure and results :
The new noninvasive Fibro test is made with a simple blood sample taken from the patient's vain. The patient should be fasting.

The test can provide a non- invasive assessment of the stage of fibrosis and grade of necro- inflammatory activity (corresponding to stages F0-F4 and grades A0-A3 of the scale system). Follow- up tests are recommended every 6 months if fibrosis is moderate, or every 12 months if fibrosis is minimal.